SSA
AXSM icon

Sierra Summit Advisors’s Axsome Therapeutics AXSM Stock Holding History

Sierra Summit Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9,224
Closed -$734K – 154
2023
Q4 		$734K Buy
+9,224
New +$617K 0.21% 66

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sierra Summit Advisors's AXSM Position: Q1 2024 in Review

Sierra Summit Advisors sold out of Axsome Therapeutics (AXSM) in Q1 2024, closing a stake of 9,224 shares — an estimated $734K sold.

Sierra Summit Advisors first reported a position in AXSM in Q4 2023 and held it in 1 quarter. The position peaked at $734K in Q4 2023. 260 funds tracked by Wall St. Rank hold AXSM as of Q1 2024.

  • Sierra Summit Advisors reported no remaining Axsome Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Sierra Summit Advisors sold 9,224 Axsome Therapeutics shares in Q1 2024, an estimated $734K.
  • Sierra Summit Advisors first reported a position in Axsome Therapeutics in Q4 2023 and held it in 1 quarter.
  • Sierra Summit Advisors's Axsome Therapeutics position peaked at $734K in Q4 2023.
  • 260 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2024.

Based on Sierra Summit Advisors's 13F filing for Q1 2024, filed 9 May 2024.